[go: up one dir, main page]

MX2018013525A - Construcciones de anticuerpo de adn para uso contra pseudomonas aeruginosa. - Google Patents

Construcciones de anticuerpo de adn para uso contra pseudomonas aeruginosa.

Info

Publication number
MX2018013525A
MX2018013525A MX2018013525A MX2018013525A MX2018013525A MX 2018013525 A MX2018013525 A MX 2018013525A MX 2018013525 A MX2018013525 A MX 2018013525A MX 2018013525 A MX2018013525 A MX 2018013525A MX 2018013525 A MX2018013525 A MX 2018013525A
Authority
MX
Mexico
Prior art keywords
pseudomonas aeruginosa
antibody constructs
use against
against pseudomonas
dna antibody
Prior art date
Application number
MX2018013525A
Other languages
English (en)
Inventor
Yan Jian
Weiner David
Patel Ami
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2018013525A publication Critical patent/MX2018013525A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen en la presente anticuerpos de ADN mono y biespecificos (DMAb) dirigidos a Pseudomonas aeruginosa; tambien se describe en la presente un metodo para generar un anticuerpo sintetico en un sujeto mediante la administracion de DMAb al sujeto; la descripción tambien proporciona un metodo para prevenir y/o tratar una infeccion de Pseudomonas aeruginosa en un sujeto utilizando dicha composicion y metodo de generacion.
MX2018013525A 2016-05-05 2017-05-05 Construcciones de anticuerpo de adn para uso contra pseudomonas aeruginosa. MX2018013525A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332363P 2016-05-05 2016-05-05
PCT/US2017/031449 WO2017193101A1 (en) 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa

Publications (1)

Publication Number Publication Date
MX2018013525A true MX2018013525A (es) 2019-06-10

Family

ID=60203552

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013525A MX2018013525A (es) 2016-05-05 2017-05-05 Construcciones de anticuerpo de adn para uso contra pseudomonas aeruginosa.

Country Status (12)

Country Link
US (1) US12492243B2 (es)
EP (1) EP3452090A4 (es)
JP (2) JP2019520085A (es)
KR (2) KR20190025826A (es)
CN (1) CN110072554A (es)
AU (2) AU2017261374B2 (es)
BR (1) BR112018072716A2 (es)
CA (1) CA3023094A1 (es)
EA (1) EA201892525A1 (es)
MX (1) MX2018013525A (es)
SG (2) SG10202011016WA (es)
WO (1) WO2017193101A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
BR112014011028B1 (pt) * 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição
CN111936513A (zh) * 2018-01-31 2020-11-13 威斯塔解剖学和生物学研究所 用于抗呼吸道合胞病毒的核酸抗体构筑体
AU2020323601A1 (en) * 2019-07-31 2022-03-03 The Wistar Institute Of Anatomy And Biology Multivalent DNA antibody constructs and use thereof
EP4003333A4 (en) * 2019-07-31 2023-11-01 The Wistar Institute for Anatomy and Biology CONSTRUCTIONS OF MULTIVALENT DNA ANTIBODIES AND THEIR USE
CN114072145B (zh) * 2020-06-01 2024-06-11 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途
CN115023438B (zh) * 2020-11-18 2024-05-03 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv或psl抗原的抗体组合以及双特异性抗体
WO2024231440A1 (en) * 2023-05-09 2024-11-14 Astrazeneca Ab Bispecific anti-pseudomonas antibodies with modified fc regions and methods of use thereof
WO2025117765A1 (en) * 2023-12-01 2025-06-05 University Of Washington Protective monoclonal antibodies to pseudomonas aeruginosa

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
US20130058936A1 (en) 2011-08-23 2013-03-07 Peter Bruenker Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
US9913830B2 (en) 2011-09-08 2018-03-13 University Of Florida Research Foundation, Incorporated Materials and methods for modulating immune responses
BR112014011028B1 (pt) * 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição
EP2776061B1 (en) 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
AU2013224851B2 (en) * 2012-03-02 2018-03-01 Ablynx Nv Pseudomonas aeruginosa PcrV binding single variable domain antibodies
AU2013341349A1 (en) * 2012-11-06 2015-05-21 Medimmune Limited Combination therapies using anti-Pseudomonas Psl and PcrV binding molecules
HK1213481A1 (zh) 2012-12-13 2016-07-08 The Trustees Of The University Of Pennsylvania Dna抗体构建体及其使用方法
US10087240B2 (en) 2013-12-13 2018-10-02 Inovio Pharmaceuticals, Inc. DNA antibody constructs and method of using same
WO2015171504A1 (en) * 2014-05-05 2015-11-12 Medimmune, Llc Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療

Also Published As

Publication number Publication date
CN110072554A (zh) 2019-07-30
JP2023058497A (ja) 2023-04-25
JP2019520085A (ja) 2019-07-18
SG10202011016WA (en) 2020-12-30
CA3023094A1 (en) 2017-11-09
US20190153076A1 (en) 2019-05-23
EP3452090A1 (en) 2019-03-13
EP3452090A4 (en) 2019-12-18
AU2017261374A1 (en) 2018-12-20
AU2017261374B2 (en) 2024-06-20
KR20230093338A (ko) 2023-06-27
SG11201809778TA (en) 2018-12-28
AU2024203766A1 (en) 2024-06-27
BR112018072716A2 (pt) 2019-02-19
US12492243B2 (en) 2025-12-09
KR20190025826A (ko) 2019-03-12
WO2017193101A1 (en) 2017-11-09
EA201892525A1 (ru) 2019-04-30

Similar Documents

Publication Publication Date Title
MX2018013525A (es) Construcciones de anticuerpo de adn para uso contra pseudomonas aeruginosa.
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
CL2019001193A1 (es) Moléculas de unión a lag-3 y métodos de uso de las mismas. (divisional solicitud 201703132).
MX2018001227A (es) Moleculas de union a pd-1 y metodos de uso de las mismas.
MX2020013348A (es) Anticuerpos biespecificos contra dll3-cd3.
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
BR112019002168A2 (pt) anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
JOP20170170B1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
EA201890028A1 (ru) Антитело, связывающее cd3 человека
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
MX2017007187A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2015017487A (es) Anticuerpos cd3 humanizados o quimericos.
EA201791270A1 (ru) Модифицированные april-связывающие антитела
GT201200318A (es) Anticuerpos hacia gdf8 humano
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2024000118A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
EA201990978A1 (ru) Антитела против pd-1
MX2017004196A (es) Anticuerpos contra ticagrelor y metodos de uso.
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.